All In Biotech

Drug Trial Radar · NCT07629544

A Study of DA-302168S in Participants With Overweight/Obesity

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants

Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

840

Planned (sponsor's estimate)

Start

Jun 19, 2026

Primary completion

Jul 9, 2027

Study completion Oct 19, 2027

Sponsor

Sponsor type
Industry
Collaborators
Peking University People's Hospital
First posted
Jun 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study aimed at evaluating the efficacy, safety, and pharmacokinetic (PK) characteristics of DA-302168S tablets in overweight or obese participants in China.

Conditions

  • Overweight and Obesity

Interventions

  • DA-302168SDrug

    A small molecule GLP-1R agonist tablet, orally administration, once daily

  • DA-302168SDrug

    A small molecule GLP-1R agonist tablet, orally administration, once daily

  • PlaceboDrug

    Matching placebo tablet will be provided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in body weightTime frame: From baseline to week 40
  2. The proportion of subjects with a body weight reduction ≥5% from baselineTime frame: From baseline to week 40

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.